Encycle Therapeutics Analysis: $10M Raised
What is Encycle Therapeutics?
Encycle Therapeutics is a Toronto-based biotech company that focuses on synthesizing drug-like macrocycles and nacellins. Their technology targets intracellular protein-protein interactions, offering potential oral alternatives to existing biologics. The company is developing nacellins for conditions like inflammatory bowel disease and fibrosis.
Location
101 College St Ste 314, Toronto, Ontario M5G 1L7, Canada
Employees
1-10
Founded
2012
Funding Status
Acquired
Product Features & Capabilities
- Nacellins targeting integrin alpha-4-beta-7
- Drug-like macrocycles for intracellular interactions
- Screening library of cell-permeable nacellins
Use Cases
Develop orally bioavailable inhibitors for IBD; Target SMURF2 for fibrosis treatment; Collaborate with pharmaceutical companies for nacellin screening; Create alternatives to monoclonal antibodies; Explore drug-like properties of nacellins
Other Considerations
Acquired by Zealand Pharma; Collaborated with multiple pharmaceutical companies; Raised funding from Takeda Ventures
See something that needs updating? Suggest edits to this profile.